Nobel laureates in Physiology or Medicine James P. Allison, PhD, and Tasuku Honjo, MD, PhD, delivered their lectures "Immune Checkpoint Blockade in Cancer Therapy: New insights, opportunities, and prospects for cures" and "Serendipities of acquired immunity," respectively, in Solna, Sweden on Friday, Dec. 7, 2018. Watch their lectures and then read articles from additional leading experts in JITC's Immune Checkpoint Therapy collection.
Nobel Lectures in Cancer Immunotherapy
Dr. Pedro Romero is full Professor of Tumor Immunology, at the Department of Fundamental Oncology, Faculty of Biology and Medicine at the University of Lausanne and Ludwig Cancer Research Center, Switzerland. In his early work, Dr. Romero was among the first to use fluorescent pMHC multimers to identify and characterize tumor antigen specific T cells infiltrating tumors in melanoma patients and pioneered modern immunomonitoring approaches to follow anti-tumor T cell responses in cancer patients. His current interests are focused on cancer immunotherapy, the understanding of tumor immune system interactions and T cell recognition of tumor antigens and molecular mechanisms governing specific T cell activation and differentiation. The work of the Romero lab has resulted in more than 290 articles published in peer reviewed journals and several patents.
Aims and scope
Journal for ImmunoTherapy of Cancer (JITC) is the open access, peer reviewed journal that publishes on all aspects of tumor immunology and cancer immunotherapy, aiming to enrich communication and advance scientific understanding in this rapidly evolving field. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.
SITC Member Discount
SITC will provide members with a 60 percent discount on article processing charges for all JITC articles submitted and accepted in 2019.
This discount must be requested prior to submission by contacting JITCEditor@sitcancer.org. Upon receiving a waiver code from this contact, authors must select option #2 on the View Publication Charges page to enter the code in the “BioMed Central Account Number” box.
Learn more about the Society for Immunotherapy of Cancer’s mission to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy at SITC Cancer Immunotherapy CONNECT.
Immune monitoring technology primers
Reviewed by the members of the SITC Immune Biomarkers Task Force, these brief primers highlight important aspects of both standardized and novel technologies available in clinical trial settings.
SITC Cancer immunotherapy guidelines
Developed by experts in the treatment of specific types of cancer, each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients. View post-publication updates from the Society for Immunotherapy of Cancer on SITC CONNECT.
Official journal of
Journal for ImmunoTherapy of Cancer is the official journal of the Society for Immunotherapy of Cancer (SITC)
- Editorial Board
- Sign up for article alerts and news from this journal
Annual Journal Metrics
44 days to first decision for reviewed manuscripts only
38 days to first decision for all manuscripts
100 days from submission to acceptance
21 days from acceptance to publication
8.676 - 2-year Impact Factor
1.416 - Source Normalized Impact per Paper (SNIP)
3.337 - SCImago Journal Rank (SJR)
6.860 - CiteScore
4,540 Altmetric mentions